AURA
$6.81
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs o...
Recent News
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline
Aura Biosciences (NASDAQ:AURA) is advancing what it describes as a novel class of therapies called virus-like drug conjugates (VDCs), with its lead program in ocular oncology now in a Phase 3 trial for early choroidal melanoma. Speaking at Leerink Partners’ Global Healthcare Conference in Miami, CEO
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference
Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel effort in bladder cancer during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference. Founder and CEO Eli de los Pinos said the company’s lead program in early-stage
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.
What Makes Aura Biosciences (AURA) a New Buy Stock
Aura Biosciences (AURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).